# Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC

## TL;DR

A new trial shows that proactive skin care can reduce severe skin side effects in lung cancer patients receiving a specific drug combination.

## Contribution

The COCOON trial introduces a structured dermatologic prophylaxis regimen that significantly reduces moderate-to-severe skin adverse events in patients treated with amivantamab and lazertinib.

## Key findings

- A structured prophylactic skin care regimen halved the incidence of grade ≥2 dermatologic adverse events.
- The regimen reduced grade ≥3 events and treatment discontinuations compared to standard reactive care.

## Abstract

Dermatologic adverse events (AEs) are a well-recognized complication of EGFR-targeted therapies, often emerging early during treatment and contributing to dose interruptions, patient discomfort, and reduced adherence. The combination of amivantamab, a bispecific EGFR-MET antibody, with lazertinib, a third-generation EGFR tyrosine kinase inhibitor, has demonstrated significant survival benefits in EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, this therapeutic advancement brings with it an increased incidence of cutaneous toxicity. At the 2025 European Lung Cancer Congress, interim findings from the phase II COCOON trial were presented, offering timely insight into a proactive approach to managing these toxicities.

This commentary summarizes and contextualizes the COCOON study, which investigated whether a structured dermatologic prophylaxis regimen could mitigate moderate-to-severe skin AEs in patients receiving first-line amivantamab plus lazertinib. The prophylactic protocol included oral doxycycline or minocycline, ceramide-based moisturization, chlorhexidine nail care, and topical clindamycin, initiated at specified intervals. Compared to standard reactive care, this strategy halved the incidence of grade ≥2 dermatologic AEs (38.6% vs. 76.5%) and reduced grade ≥3 events and treatment discontinuations.

The COCOON results emphasize the clinical value of anticipating EGFR inhibitor-related toxicities through multidisciplinary supportive care. By implementing straightforward, low-cost interventions, clinicians can significantly improve tolerability and maintain dose intensity, maximizing therapeutic benefit. As this data informs future updates to clinical practice guidelines, it reinforces the need to integrate dermatologic prevention into first-line treatment planning for EGFR-mutant NSCLC. This commentary highlights COCOON’s relevance as a model for supportive care innovation in targeted oncology.